Sign up to save your data!
Some tips to help get started:
Processing...
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: The trial involves patients with advanced solid tumors and documented KRAS mutations, including NSCLC, CRC, and PDAC, testing the safety and preliminary efficacy of PF-07985045, a KRAS inhibitor, as a monotherapy and in combination with other therapies such as chemotherapy, targeted treatments, and immunotherapies.
ClinicalTrials.gov ID: NCT06704724
HealthScout AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.
ClinicalTrials.gov ID: NCT06774963
HealthScout AI summary: This trial involves patients with advanced or metastatic EGFR-mutant non-small cell lung cancer who have progressed on third-generation EGFR-TKIs, exploring the safety and efficacy of BG-60366, an oral CDAC designed to degrade mutant EGFR.
ClinicalTrials.gov ID: NCT06685718
HealthScout AI summary: This study targets patients with advanced colorectal, non-small cell lung, and gastric cancers expressing CEACAM5 by investigating the safety and preliminary efficacy of the investigational drug BMS-986490, with or without bevacizumab. Eligible participants must have previously progressed on standard therapies and have an ECOG performance status of 0 or 1.
ClinicalTrials.gov ID: NCT06730750
HealthScout AI summary: This trial involves adult patients with advanced solid tumors, focusing on gastric, GEJ, esophageal adenocarcinomas, and NSCLC, testing KK2269, a bispecific antibody targeting CD40 and EpCAM, alone and in combination with docetaxel to assess safety and tolerability.
ClinicalTrials.gov ID: NCT06266299
HealthScout AI summary: This trial involves adult patients with advanced or metastatic Claudin-1 positive squamous solid tumors, including selected cases of squamous non-small cell lung cancer, head and neck, esophageal, or cutaneous squamous cell carcinoma that have become refractory or intolerant to standard therapies. It investigates ALE.P02, an antibody-drug conjugate targeting Claudin-1, aiming to deliver a tubulin inhibitor directly to CLDN1+ cancer cells.
ClinicalTrials.gov ID: NCT06747585
HealthScout AI summary: This trial targets adults with advanced solid tumors, evaluating the safety and preliminary efficacy of the investigational antibody-drug conjugate BMS-986507 with either osimertinib, an EGFR tyrosine kinase inhibitor, or pembrolizumab, a PD-1 inhibitor, in patients with at least one measurable lesion and a good performance status.
ClinicalTrials.gov ID: NCT06618287
HealthScout AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.
ClinicalTrials.gov ID: NCT04969315
HealthScout AI summary: This trial investigates the safety and anti-tumor activity of the investigational drug BMS-986488, alone or combined with adagrasib, cetuximab, or nivolumab, in adults with advanced malignant tumors, including specific cohorts with ccRCC, NSCLC (KRAS G12C mutation), ccOC, and CRC (KRAS G12C mutation).
ClinicalTrials.gov ID: NCT06764771
HealthScout AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.
ClinicalTrials.gov ID: NCT06253871
